Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on May 5th. The trade occurred in the Representative's "MARJORIE IRA" account.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Occidental Petroleum NYSE: OXY on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Starbucks NASDAQ: SBUX on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 5/5/2025.
- Purchased $1,001 - $15,000 in shares of Impinj NASDAQ: PI on 5/5/2025.
Gilead Sciences Stock Performance
GILD traded down $1.30 on Friday, hitting $96.86. The company's stock had a trading volume of 13,140,489 shares, compared to its average volume of 7,599,780. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market cap of $120.61 billion, a P/E ratio of 261.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company's 50 day simple moving average is $107.23 and its 200-day simple moving average is $99.23.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the previous year, the company earned ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.26%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
Institutional Investors Weigh In On Gilead Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth about $25,000. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Finally, Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the 1st quarter worth $29,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Transactions at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at $17,893,713.60. This represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 160,605 shares of company stock worth $16,718,136 over the last quarter. 0.27% of the stock is currently owned by insiders.
Analysts Set New Price Targets
GILD has been the subject of a number of research reports. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Friday, April 25th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.
View Our Latest Research Report on Gilead Sciences
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.
Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
